The Filings Report

American Healthcare REIT, Inc.

AHRNYSECIK 1632970Real Estate / REITsfiscal year ends December45 quarters since 2015

Revenue, Q2 FY2026
$635M
+26.6% on Q2 FY2025
Net income
$31M
+208.9% on Q2 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$0.16
+166.7% on Q2 FY2025
Revenue, TTM
$2.3B
trailing four quarters
Net margin, TTM
5.2%
net income $121M
Free cash flow, TTM
—
Cash and equivalents
$157M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+29.3%
218M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$179M
1.5% of market value
Market value
$11.7B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 7, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, American Healthcare REIT, Inc. reported revenue of $635M, +26.6% on Q2 FY2025, and net income of $31M (+208.9%). Operating margin was 21.6%. Diluted earnings per share were $0.16.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 7, 2026.

Revenue and net incomeRevenueNet income
−$200M$0$200M$400M$600M$800MQ3'22, Revenue: $368MQ3'22, Net income: −$14MQ3'22Q4'22, Revenue: $399MQ4'22, Net income: −$48MQ4'22Q1'23, Revenue: $409MQ1'23, Net income: −$26MQ1'23Q2'23, Revenue: $411MQ2'23, Net income: −$12MQ2'23Q3'23, Revenue: $416MQ3'23, Net income: −$6MQ3'23Q4'23, Revenue: $433MQ4'23, Net income: −$27MQ4'23Q1'24, Revenue: $452MQ1'24, Net income: −$4MQ1'24Q2'24, Revenue: $458MQ2'24, Net income: $2MQ2'24Q3'24, Revenue: $477MQ3'24, Net income: −$4MQ3'24Q4'24, Revenue: $497MQ4'24, Net income: −$32MQ4'24Q1'25, Revenue: $497MQ1'25, Net income: −$7MQ1'25Q2'25, Revenue: $501MQ2'25, Net income: $10MQ2'25Q3'25, Revenue: $532MQ3'25, Net income: $56MQ3'25Q4'25, Revenue: $564MQ4'25, Net income: $11MQ4'25Q1'26, Revenue: $610MQ1'26, Net income: $24MQ1'26Q2'26, Revenue: $635MQ2'26, Net income: $31MQ2'26−$200M$0$200M$400M$600M$800MQ3'22, Revenue: $368MQ3'22, Net income: −$14MQ4'22, Revenue: $399MQ4'22, Net income: −$48MQ4'22Q1'23, Revenue: $409MQ1'23, Net income: −$26MQ2'23, Revenue: $411MQ2'23, Net income: −$12MQ2'23Q3'23, Revenue: $416MQ3'23, Net income: −$6MQ4'23, Revenue: $433MQ4'23, Net income: −$27MQ4'23Q1'24, Revenue: $452MQ1'24, Net income: −$4MQ2'24, Revenue: $458MQ2'24, Net income: $2MQ2'24Q3'24, Revenue: $477MQ3'24, Net income: −$4MQ4'24, Revenue: $497MQ4'24, Net income: −$32MQ4'24Q1'25, Revenue: $497MQ1'25, Net income: −$7MQ2'25, Revenue: $501MQ2'25, Net income: $10MQ2'25Q3'25, Revenue: $532MQ3'25, Net income: $56MQ4'25, Revenue: $564MQ4'25, Net income: $11MQ4'25Q1'26, Revenue: $610MQ1'26, Net income: $24MQ2'26, Revenue: $635MQ2'26, Net income: $31MQ2'26

Net income losses drawn in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$50M$100M$150M$200MQ3'22, Cash and equivalents: $79MQ3'22Q4'22, Cash and equivalents: $65MQ4'22Q1'23, Cash and equivalents: $41MQ1'23Q2'23, Cash and equivalents: $48MQ2'23Q3'23, Cash and equivalents: $35MQ3'23Q4'23, Cash and equivalents: $43MQ4'23Q1'24, Cash and equivalents: $77MQ1'24Q2'24, Cash and equivalents: $52MQ2'24Q3'24, Cash and equivalents: $68MQ3'24Q4'24, Cash and equivalents: $77MQ4'24Q1'25, Cash and equivalents: $86MQ1'25Q2'25, Cash and equivalents: $133MQ2'25Q3'25, Cash and equivalents: $147MQ3'25Q4'25, Cash and equivalents: $115MQ4'25Q1'26, Cash and equivalents: $119MQ1'26Q2'26, Cash and equivalents: $157MQ2'26$0$50M$100M$150M$200MQ3'22, Cash and equivalents: $79MQ4'22, Cash and equivalents: $65MQ4'22Q1'23, Cash and equivalents: $41MQ2'23, Cash and equivalents: $48MQ2'23Q3'23, Cash and equivalents: $35MQ4'23, Cash and equivalents: $43MQ4'23Q1'24, Cash and equivalents: $77MQ2'24, Cash and equivalents: $52MQ2'24Q3'24, Cash and equivalents: $68MQ4'24, Cash and equivalents: $77MQ4'24Q1'25, Cash and equivalents: $86MQ2'25, Cash and equivalents: $133MQ2'25Q3'25, Cash and equivalents: $147MQ4'25, Cash and equivalents: $115MQ4'25Q1'26, Cash and equivalents: $119MQ2'26, Cash and equivalents: $157MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 7, 2026.

American Healthcare REIT, Inc. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 13, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue635610564532501497497477+26.6%
Cost of revenue525512480455426432431417+23.1%
Gross profit—————————
Research and development—————————
Selling, general and administrative2018171415131212+33.1%
Operating income137126112106103959994+32.9%
Other income (expense)(11)(15)(28)(7)(36)(45)(71)(37)+67.8%
Pretax income312393611(6)(32)(3)+186.5%
Income tax0(1)(2)(21)1100−100.4%
Net income3124115610(7)(32)(4)+208.9%
Diluted EPS ($)0.160.13—0.330.06(0.04)—(0.03)+166.7%
Diluted shares (millions)193188—170161157—134—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 7, 2026.

American Healthcare REIT, Inc. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 13, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents157119115147133867768+17.5%
Short-term investments—————————
Total current assets—————————
Total assets5,7045,5995,4264,7704,5074,4644,4884,677+26.6%
Total current liabilities—————————
Long-term debt—————————
Total liabilities1,9622,0772,0662,0502,0442,1592,1842,420−4.0%
Stockholders’ equity3,6953,4823,3212,6782,4212,2622,2612,207+52.6%
Shares outstanding (millions)218193188177169159158153—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 7, 2026.

American Healthcare REIT, Inc. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 13, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow119815510771616063+66.0%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization7267554942414744+72.0%
Share repurchases——000000—
Dividends paid4847434140403833+19.4%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 27, 2026.

Income statement

American Healthcare REIT, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Mar 22, 2024FY2022ended Dec 31, 2022filed Mar 17, 2023FY2021ended Dec 31, 2021filed Mar 25, 2022FY2020ended Dec 31, 2020filed Mar 26, 2021FY2019ended Dec 31, 2019filed Mar 19, 2020FY2018ended Dec 31, 2018filed Mar 18, 2019FY2017ended Dec 31, 2017filed Mar 8, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Mar 7, 2016
Revenue2,0951,8841,6691,4121,1241,0691,0993760—
Cost of revenue1,7941,6541,5021,2821,0309949683071—
Gross profit———————————
Research and development———————————
Selling, general and administrative59484843432730941—
Operating income415364307302213218221——(5)—
Other income (expense)(115)(164)(147)(159)(76)(86)(80)————
Pretax income49(34)(76)(73)(52)61(9)1(5)—
Income tax(22)2111(3)2000—
Net income70(38)(71)(81)(48)2(5)(8)1(5)—
Diluted EPS ($)0.42(0.29)(1.08)(1.24)(0.95)0.05(0.03)————
Diluted shares (millions)16713166665045182————

Balance sheet

American Healthcare REIT, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Mar 22, 2024FY2022ended Dec 31, 2022filed Mar 17, 2023FY2021ended Dec 31, 2021filed Mar 25, 2022FY2020ended Dec 31, 2020filed Mar 26, 2021FY2019ended Dec 31, 2019filed Mar 19, 2020FY2018ended Dec 31, 2018filed Mar 18, 2019FY2017ended Dec 31, 2017filed Mar 8, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Mar 7, 2016
Cash and equivalents115774365821135335720
Short-term investments———————————
Total current assets———————————
Total assets5,4264,4884,5784,7874,5803,2351,0688964801430
Total current liabilities———————————
Long-term debt———————————
Total liabilities2,0662,1843,1193,1372,7512,160477337126510
Stockholders’ equity3,3212,2611,2701,4001,581866590——920
Shares outstanding (millions)18815865————————

Cash flow statement

American Healthcare REIT, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Mar 22, 2024FY2022ended Dec 31, 2022filed Mar 17, 2023FY2021ended Dec 31, 2021filed Mar 25, 2022FY2020ended Dec 31, 2020filed Mar 26, 2021FY2019ended Dec 31, 2019filed Mar 19, 2020FY2018ended Dec 31, 2018filed Mar 18, 2019FY2017ended Dec 31, 2017filed Mar 8, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Mar 7, 2016
Operating cash flow29417699148182191171512(4)—
Capital expenditures———————————
Free cash flow (CFO − capex)———————————
Depreciation and amortization1881791831681339911133141—
Share repurchases0002102390310—
Dividends paid16412176512327631461—

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$189K
2 sales by 1 insider; officers and directors $189K
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$5M
10 sales by 3 insiders; officers and directors $5M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 25, 2026Foster Mark E.EVP, GC & Secretaryopen-market sale1,500$52.06$78K50,117Sep 28, 2026
Sep 1, 2026Foster Mark E.EVP, GC & Secretaryopen-market sale10b5-12,000$55.39$111K51,617Sep 1, 2026
Jul 21, 2026Prosky DannyDirectoraward2,594$0.00—313,592Aug 4, 2026
Jul 21, 2026Prosky DannyDirectortax withholding59,945$56.66$3M286,524Jul 22, 2026
Jul 21, 2026Prosky DannyDirectoroption exercise30,886——317,410Jul 22, 2026
Jul 21, 2026Prosky DannyDirectortax withholding16,663$56.66$944K300,747Jul 22, 2026
Jul 21, 2026Prosky DannyDirectoroption exercise20,912——321,659Jul 22, 2026
Jul 21, 2026Prosky DannyDirectortax withholding11,283$56.66$639K310,376Jul 22, 2026
Jul 21, 2026Prosky DannyDirectoraward2,594$0.00—312,970Jul 22, 2026
Jun 26, 2026Peay BrianChief Financial Officeropen-market sale25,000$50.70$1M152,700Jun 29, 2026
Jun 24, 2026Foster Mark E.EVP, GC & Secretaryopen-market sale2,500$48.58$121K52,995Jun 26, 2026
Jun 24, 2026Richardson ValerieDirectoraward2,594$0.00—20,656Jun 26, 2026
Jun 24, 2026O'Quinn Marvin RDirectoraward2,594$0.00—20,656Jun 26, 2026
Jun 24, 2026Smith Wilbur H IIIDirectoraward2,594$0.00—35,013Jun 26, 2026
Jun 24, 2026Streiff Mathieu B.Directoraward2,594$0.00—34,971Jun 26, 2026
Jun 24, 2026Flornes Brian J.Directoraward2,594$0.00—33,020Jun 26, 2026
Jun 24, 2026Hurley DianneDirectoraward2,594$0.00—34,037Jun 26, 2026
Jun 24, 2026Estes Scott ADirectoraward2,594$0.00—21,489Jun 26, 2026
Jun 1, 2026Foster Mark E.EVP, GC & Secretaryopen-market sale10b5-12,000$48.32$97K55,495Jun 3, 2026
Apr 6, 2026Foster Mark E.EVP, GC & Secretaryoption exercise2,986——59,107Apr 8, 2026
Apr 6, 2026Foster Mark E.EVP, GC & Secretarytax withholding1,612$48.09$78K57,495Apr 8, 2026
Apr 6, 2026Oh Stefan K.L.Chief Investment Officeroption exercise3,185——98,615Apr 8, 2026
Apr 6, 2026Oh Stefan K.L.Chief Investment Officertax withholding1,621$48.09$78K96,994Apr 8, 2026
Apr 6, 2026Willhite Gabriel MChief Operating Officeroption exercise6,768——151,819Apr 8, 2026
Apr 6, 2026Willhite Gabriel MChief Operating Officertax withholding3,654$48.09$176K148,165Apr 8, 2026

Full insider history for American Healthcare REIT, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
American Healthcare REIT, Inc., CIK 1632970 on EDGAR
Extract generated
November 4, 2026
Withheld
3 line-years whose four quarters do not sum to the filed year: revenue FY2018, net income FY2019, revenue FY2019
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: revenue FY2017
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: not filed
Total assets: Assets
Total current liabilities: not filed
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/AHR.json